登录/ 注册

Novo Nordisk shares fell, wiping away the last gains Wegovy's launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's tirzepatide in a trial

02-23 22:15
利好
利空

热门资讯